Skye Bioscience, Inc. Quarterly report pursuant to Section 13 or 15(d)

Asset Acquisition (Tables)

9 Months Ended

Sep. 30, 2023

Below is a summary of the total consideration, assets acquired and the liabilities assumed in connection with the BRB Acquisition:


	August 18, 2023

Purchase consideration
Common stock	$	21,609,586	(a)
Total consideration	$	21,609,586

Assets acquired and liabilities assumed:
IPR&D asset	$	21,215,214
Cash and cash equivalents	1,076,740
Prepaid expenses	4,800
Accounts payable	(73,473)
Other current liabilities	(613,695)
Total net assets acquired	$	21,609,586

(a) Equal to the aggregate common shares issued of 5,436,378, multiplied by the Company's closing stock price of $3.98 as of August 18, 2023.